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AbsTRACT
Ischaemic heart disease (IHD), in particular acute 
coronary syndrome (ACS), comprising ST- elevation 
myocardial infarction, non- ST- elevation myocardial 
infarction and unstable angina, is the leading cause of 
death worldwide. Age is a major predictor of adverse 
outcome following ACS. COVID-19 infection seems to 
escalate the risk in older patients with heart disease. 
Increasing odds of in- hospital death is associated with 
older age following COVID-19 infection. Importantly, 
it seems older patients with comorbidities such as 
cardiovascular disease (CVD), in particular IHD, diabetes 
and hypertension, are at the highest risk of mortality 
following COVID-19 infection. The evidence is sparse on 
the optimal care of older patients with ACS with lack of 
robust randomised controlled trials. In this setting, with 
the serious threat imposed by the COVID-19 pandemic 
in the context of rapidly evolving knowledge with much 
unknown, it is important to weigh the risks and benefits 
of treatment strategies offered to older patients. In 
cases where risks outweigh the benefits, it might not 
be an unreasonable option to treat such patients with a 
conservative or a palliative approach. Further evidence 
to elucidate whether invasive management is beneficial 
in older patients with ACS is required out- with the 
COVID-19 pandemic. Though it is hoped that the actual 
acute phase of COVID-19 infection will be short lived, 
it is vital that important clinical research is continued, 
given the long- term benefits of ongoing clinical research 
for patients with long- term conditions, including CVD. 
This review aimed to evaluate the challenges and the 
management strategies in the care of older patients 
presenting with ACS in the context of the COVID-19 
pandemic.
InTRODuCTIOn
Ischaemic heart disease (IHD), in particular acute 
coronary syndrome (ACS), comprising ST- elevation 
myocardial infarction (STEMI), non- ST- elevation 
myocardial infarction (NSTEMI) and unstable 
angina, is the leading cause of death worldwide.1 
Older patients are an increasing proportion of 
patients with myocardial infarction (MI) as popu-
lation demographics in developed countries change 
and medical science advances.2 One of the major 
predictors of adverse outcome following ACS is 
age, yet patients aged ≥75 years are often excluded 
or under- represented in clinical trials.3 4
COVID-19 infection seems to escalate the risk in 
older patients with cardiovascular disease (CVD), 
diabetes and hypertension.5 6 There is increasing 
odds of in- hospital death associated with older age 
as a result of COVID-19 infection.5 Regardless of 
the COVID-19 pandemic, the optimal standardised 
care of ACS in older patients is not clear due to 
lack of robust evidence, clinicians’ reluctance due to 
fear of complications (bleeding and comorbidities), 
perception of poor outcomes or low success rates 
in older patients, and patients presenting later after 
symptom onset or with an atypical presentation.7 
The uncertainty in the optimal care of the older 
patients with ACS is further escalated in the context 
of the COVID-19 pandemic. This review aimed to 
evaluate the challenges and the management strat-
egies in the care of older patients presenting with 
ACS in the context of the COVID-19 pandemic.
CVD and COVID-19 in older adults
In late 2019, a novel coronavirus, named 
COVID-19 or severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2), emerged in Wuhan, 
China. It rapidly spread and the WHO declared it 
a pandemic on 11 March 2020. The virus is similar 
to the original severe acute respiratory syndrome 
(SARS) outbreak that appeared in the early 2000s.8 
The two viruses are both likely zoonotic in origin, 
specifically derived from bats.9 Pangolin species 
appear to be a natural reservoir of SARS- CoV-2- like 
CoVs.10 The most common symptoms on admission 
are fever (98%), cough (76%), dyspnoea (55%) and 
myalgias or fatigue (up to 44%).11 Among patients 
with a mean age of 70 years, the most common 
presenting symptoms were shortness of breath 
(76%), fever (52%) and cough (48%).12
SARS- CoV-2 uses the ACE2 receptor to enter 
the host cells. The spike protein in SARS- CoV-2 
anchors to the S1 subunit of the ACE2 receptor.13 
Viral cell entry requires the transmembrane serine 
protease 2 expressed on host cells to perform crit-
ical protein priming that leads to conformational 
changes, viral cell entry and cell infection. ACE2 
is significantly expressed in the lungs, endothe-
lium, heart, kidneys and gastrointestinal system.14 
Those affected by cardiovascular comorbidities, 
such as diabetes or hypertension, are grossly over- 
represented in severe cases of COVID-19.15 Since 
patients with these conditions have upregulated 
ACE2 receptors with possible hypersecretion of 
ACE2, these patients are particularly susceptible to 
COVID-19 infection (figure 1).
COVID-19 infection seems to have the following 
effects on older patients1: poor outcomes in 
older patients and those with CVD,2 increased 
risk of CVD with COVID-19 infection or acute 
COVID-19 cardiovascular syndrome (ACovCS),3 
indirect adverse consequences on CVD and MI. In 
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Figure 1 Hypothesised pathogenesis of acute cardiac injury in older patients. AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; 
CCL5, chemokine ligand 5; CK, creatine kinase; CXCL8, C- X- C motif chemokine ligand 8; GI, gastrointestinal; IFN-1, interferon type 1; LDH, lactate 
dehydrogenase; Na, sodium; RAAS; renin–angiotensin–aldosterone system; SARS- CoV-2, severe acute respiratory syndrome coronavirus 2; Th1, type 1 
T- helper cell.
the context of the COVID-19 pandemic, patients can present 
with the typical type 1 MI or ACovCS.16 Clinical judgement and 
COVID-19 clinical characteristics might help in the differentia-
tion of the two conditions.
Poor outcomes in older patients and those with CVD
Morbidity
COVID-19 is particularly deadly in older patients and those 
with pre- existing comorbidities such as respiratory disease or 
CVD.5 14 17 Up to 86% of older adults with COVID-19 infection 
presented with comorbidities, and the most significant ones were 
chronic kidney disease (48%), congestive heart failure (43%), 
chronic obstructive pulmonary disease (33%) and diabetes 
(33%).12 Another study showed that hypertension (17%), 
diabetes (8%) and CVD (5%) were the most prevalent comorbid-
ities in those infected with COVID-19.18 Hypertension (relative 
risk (RR) 2.03, 95% CI 1.54 to 2.68, p<0.00001) and cardia- 
cerebrovascular (RR 3.30, 95% CI 2.030 to 5.36, p<0.00001) 
disease were significantly more common in COVID-19- infected 
patients in intensive care unit.19
Intensive care admission and adult respiratory distress syndrome 
(ARDS)
Most older adults have some form of organ damage occur-
ring due to SARS- CoV-2, including ARDS (71%), acute kidney 
injury (AKI) (20%), cardiac injury (33%) and liver dysfunction 
(15%), and 67% required vasopressor support for treatment.12 
In a retrospective cohort study of 201 patients in Wuhan,17 old 
age increased the likelihood of developing ARDS (HR 3.26, 
95% CI 2.08 to 5.11) and progressing from ARDS to death (HR 
6.17, 95% CI 3.26 to 11.67). Patients who developed ARDS 
compared with those who did not were more likely to have 
comorbidities such as diabetes (19% vs 5.1%) and hypertension 
(27.4% vs 13.7%). This may be more relevant to older women 
with ACS as they are more likely to have hypertension than 
men.20
Mortality
In- hospital death following COVID-19 infection is associated 
with older age (OR 1.10, 95% CI 1.03 to 1.17, p=0·0043).5 
In the UK as per the Office of National Statistics, 24.6% of 
COVID-19 deaths were among those aged 75–84 years.21 In 
another study, case fatality rate (CFR) in patients aged over 60 
years without comorbidities was 1.4%, whereas the CFR was 
13.2% for patients with CVD, 9.2% for patients with diabetes, 
8.4% for patients with hypertension, 8% for patients with 
chronic respiratory disease and 7.6% for patients with cancer.22 
One study on 46 fatal cases of SARS- CoV-2, in which 84% of 
patients were over the age of 60 years, found that diabetes is 
likely associated with increased mortality.11 High Sequential 
Organ Failure Assessment score (OR 5.65, 95% CI 2.61 to 
12.23, p<0.0001) and d- dimer>1 µg/mL (OR=18.42, 95% CI 
2.64 to 128.55, p=0.0033) on admission were associated with 
poor prognosis. There is high mortality among patients who 
require mechanical ventilation.5
Increased risk of CVD with COVID-19 infection
It is well documented that pneumonia, including that from viral 
causes, may precipitate MI.23 Influenza pandemics characteristi-
cally have reported cardiac death as the the most common cause 
of death.24 The pathogenesis of ACovCS infection may involve 
direct viral myocarditis, stress cardiomyopathy or cytokine storm 
due to imbalance of type 1 and type 2 T- helper cells.14 Signifi-
cantly higher levels of cytokines and chemokines were observed 
in infected patients, with severe cases showing evidence of high 
levels of proinflammatory cytokines.25 This cytokine storm 
may precipitate multiorgan dysfunction. Marked inflammatory 
response can also lead to the development of disseminated intra-
vascular coagulopathy in critically ill patients, causing microvas-
cular thrombosis in coronary circulation.
In a recent study,14 5 of the first 41 COVID-19- infected 
patients in Wuhan exhibited myocardial injury demonstrated 
by raised high- sensitivity cardiac troponin I (hs- cTnI). Some 
patients presented primarily with cardiac symptoms, such 
 o
n
 June 8, 2020 at BVA. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2020-317011 on 22 May 2020. Downloaded from 
3Rowland B, Kunadian V. Heart 2020;0:1–6. doi:10.1136/heartjnl-2020-317011
Review
Figure 2 Individualised care of older patients. ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; Rx, treatment.
as chest pain, rather than fever and cough. In a report by the 
National Health Commission of China, 11.8% of patients who 
died of COVID-19 infection without underlying CVD exhibited 
evidence of ‘substantial heart damage’.14 The rise in hs- cTnI 
appears to continue throughout the illness in patients who die. 
There is also evidence of some patients with COVID-19 experi-
encing substantial CVD acutely with acute cardiac injury (7.2%), 
shock (8.7%) and arrhythmia (16.7%).26 Acute cardiac injury 
was significantly associated with intensive care patients (RR 
13.48, 95% CI 3.60 to 50.47, p=0.0001).19
A cohort study of 416 patients observed that those with acute 
cardiac injury required non- invasive (46.3% vs 3.9%, p<0.001) 
or invasive mechanical ventilation (22% vs 4.2%, p<0.001) 
at a greater rate, and complications were more common, such 
as ARDS (58.5% vs 14.7%, p<0.001), AKI (8.5% vs 0.3%, 
p<0.001), electrolyte disturbance (15.9% vs 5.1%, p=0.003), 
hypoproteinaemia (13.4% vs 4.8%, p=0.01) and coagulation 
disorders (7.3% vs 1.8%, p=0.02).27 Importantly, myocardial 
injury is significantly associated with fatal outcome of COVID-
19- infected patients with CVD.28 Distinction between ACovCS 
and true ACS might be challenging in older patients.
Long-term cardiovascular risks associated with COVID-19
The long- term cardiovascular risks associated with COVID-19 
are uncertain.26 Due to its similarity to SARS, there is a reason-
able hypothesis that there might be extrapulmonary effects. 
This could be a future significant source of morbidity in older 
patients with ACS and may form part of treatment consider-
ations. Studies of SARS survivors in long- term follow- up have 
shown significant morbidity. For example, a small study of 25 
patients showed disrupted lipid metabolism (68%), disrupted 
glucose metabolism (60%) and cardiovascular system abnormal-
ities (44%) at follow- up.26 There is also a suggestion that those 
who have recovered may be at increased risk of MI.29 The exact 
nature and magnitude of any long- term cardiovascular morbidity 
of COVID-19 in older patients remain to be seen.
Indirect consequences of the COVID pandemic on CVD and MI
During the COVID-19 pandemic, studies have shown approx-
imately 40% reduction in STEMI activations in the cardiac 
catheterisation laboratories.30 Patients with STEMI may delay 
attending hospital after the onset of their symptoms.31 There is 
an increase in time to presentation, length of time from arrival 
at the hospital to successful percutaneous coronary intervention 
(PCI) and arrival at the catheterisation lab to successful PCI, 
which might be due to fear of the pandemic or reluctance to 
be a burden on healthcare. More stringent infection control 
measures, such as detailed travel and contact history before 
transfer to the lab, more time taken to don protective gear in 
the lab and interventional cardiologists being inexperienced in 
performing PCI while wearing protective gear, also contribute 
to delays. Catheterisation labs operate under positive pressure 
and thus pose a particular risk of spreading the infection if the 
patient undergoing the procedure is infected. Clearly, protective 
measures vary between hospitals globally. Moreover, this may 
worsen as the crisis becomes more severe. For example, clini-
cians may not wish to take on the risk of complications with 
PCI as there may be no capacity within the hospital to go to 
critical care, for instance, or clinicians may wish to discharge 
their patient as quickly as possible to limit the chance of spread 
of infection.
Management of older patients with ACs in the COVID-19 
pandemic
It seems prudent to employ COVID-19 pandemic- specific diag-
nosis and treatment protocols for the management of older 
patients with ACS. This is particularly important in the context 
of seemingly ubiquitous evidence showing older patients with 
cardiovascular morbidity are at increased risk, along with 
possible difficulties in healthcare resource provision, and prob-
able changes in timing of presentation and treatment. How best 
to treat the older patients with ACS is already a complex ques-
tion with limited evidence. In a pandemic situation that particu-
larly targets the old and frail comorbid patient, the weighing up 
of the benefits of treatments and provision of care becomes both 
clinically and ethically challenging (figure 2).
COVID-ACS protocols
Many countries have adopted the public health approach of self- 
isolation/shielding, especially for the older population. This in 
itself poses a myriad of challenges—both in mental and phys-
ical health—and necessitates the implementation of some sort 
of systematic support for these patients.32 Those with fever 
or respiratory symptoms should first attend a fever outpatient 
clinic and then be admitted to an isolation ward for rapid testing, 
epidemiological history and body temperature reading. A recent 
study examined the ethics of allocation of limited resources in 
 o
n
 June 8, 2020 at BVA. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2020-317011 on 22 May 2020. Downloaded from 
4 Rowland B, Kunadian V. Heart 2020;0:1–6. doi:10.1136/heartjnl-2020-317011
Review
the COVID-19 pandemic and gave recommendations to aid 
clinician decision making.33
1. Apply consistently a utilitarian approach of maximising lives 
saved and life- years created.
2. Testing and therapeutics should go first to front- line health-
care workers.
3. For patients with similar prognoses, random allocation of 
resources rather than first- come first- served should be em-
ployed in the case of urgent need.
4. Prioritisation should be specific for an intervention and 
should reflect the evolving scientific literature, for example, 
vaccines going to the older patients first.
5. Participants in COVID-19 research should have increased 
priority.
6. There should be no difference in allocating resources be-
tween patients with COVID-19 and other patients.
Acute COVID-19 cardiovascular syndrome
Given the high rate of myocardial injury associated with 
COVID-19 infection, it is important to rule out ACovCS16 
prior to consideration of ACS treatment. A proposed manage-
ment of ACovCS is previously described.16 A recent document 
provides guidance on cardiac imaging during the COVID-19 
pandemic.34 Coronary CT angiography can also exclude 
or confirm ACS in COVID-19 pneumonia where elevated 
troponins are common.
ST-elevation myocardial infarction
Primary percutaneous coronary intervention (PPCI) has 
drastically improved outcomes for all ages of patients with 
STEMI since its widespread adoption.35 There are very few 
randomised controlled trials (RCTs) that have evaluated the 
benefit of an invasive strategy in older patients with STEMI 
(online supplementary table 1). Current European Society 
of Cardiology guidelines recommend that there is no upper 
age limit for consideration for PPCI.36 Ongoing RCTs aim to 
evaluate the benefit of PPCI for STEMI in older patients.37 38 
Among those with a definitive diagnosis of type 1 STEMI, in 
the context of lack of robust evidence in the care of the older 
patients with a diagnosis of STEMI, during the COVID-19 
pandemic, PPCI should be considered for all patients. When 
PPCI poses logistical challenges, for example, time delay (time 
to PCI) of >120 min,36 thrombolysis might not be an unrea-
sonable strategy in these patients.
Non-STEMI
During 15 years of follow- up of the FRagmin and Fast Revascu-
larization during InStability in coronary artery disease (FRISC) 
II trial, an early invasive treatment strategy in patients with non 
ST elevation acute coronary syndrome (NSTE- ACS) postponed 
the occurrence of death or MI by an average of 18 months. 
The difference was mainly driven by postponement of new MI, 
whereas the early difference in mortality alone was not sustained 
over time.39 Older patients are a rapidly increasing proportion 
of patients with NSTE- ACS.40 Patients with NSTEMI are more 
likely to be older than patients with STEMI.41 However, small- 
sized RCTs in older patients with NSTEMI have shown mixed 
results, as summarised in online supplementary table 2. Frailty 
and comorbidities play an important role in the care of older 
patients with ACS and should be taken into consideration in 
deciding the treatment strategies. In a previous study, frailty was 
associated with a higher risk of major adverse cardiovascular 
event (MACE) (a composite of all- cause mortality, MI, stroke, 
unplanned revascularisation and major bleeding) at 1 year 
following invasive procedure for older patients with NSTEACS 
(HR 2.79, 95% CI 1.28 to 6.08, p=0.01) compared with robust 
patients.42 Frailty is a significant predictor for all- cause mortality 
after PCI (HR 2.97, 95% CI 1.56 to 5.66, p=0.001).43 Cogni-
tively impaired patients had a higher risk of MACE (a composite 
of all- cause mortality, MI, stroke, unplanned revascularisation 
and major bleeding) during follow- up (p=0.047).44 Ongoing 
studies aim to evaluate the outcomes between invasive and 
conservatively managed groups in older patients,45 46 taking into 
consideration frailty and other comorbidities. In the context of 
lack of robust evidence in the care of older patients with a defin-
itive diagnosis of NSTEMI, during the COVID-19 pandemic, 
an initial conservative approach might not be an unreasonable 
strategy.
Palliative care and advanced care planning
For older patients who are frail and with multiple comorbidities, 
refraining from more active therapy may be the most humane 
and appropriate approach in many patients with provision of 
palliative care.47 Given the high mortality associated with older 
patients with ACS and its exacerbation with COVID-19 infec-
tion, it is important for the clinical care team to have high- 
quality discussions where feasible about advance care planning 
and about goals of care with patients or their families.48
Optimal cardiovascular secondary prevention therapy
It is also important that patients with ACS are prescribed guideline- 
recommended secondary prevention therapy.36 49 Because of the 
pathology of how the virus infects its hosts, there has been some 
suggestion that ACE inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) may exacerbate the virus.9 14 50 However, this is 
likely unfounded based on the currently available data.50 With-
drawal of these medications would be ill advised due to their 
significant impact on reducing cardiovascular mortality,50 and in 
fact, a recent study suggests that inpatient use of ACEI/ARB was 
associated with lower risk of all- cause mortality compared with 
ACEI/ARB non- users.w1 Rapid research to determine correla-
tion with outcomes is necessary as these medications may be a 
valuable treatment modality or may be harmful to those already 
at greater risk.w2 Careful evaluation of the need for antithrom-
botic therapy should also be considered in COVID-19- infected 
patients.w3
Management of the catheter lab in the COVID-19 pandemic
Cardiology associations and societies have provided consensus 
documents on the management of the invasive procedure room 
and the personnel.w4–w7 Patients must wear a surgical mask 
while waiting preprocedure and postprocedure, there should be 
maximum coordination to minimise wait times, and all patients 
should have a detailed symptomatology, contact history and 
temperature reading before entering the lab. The consensus 
documents provides further specific information for protec-
tive equipment use, as well as handling and management of the 
patients during the procedure that may be a useful guide to the 
interventional cardiology team.
Future directions
Future such epidemics may emerge with a similar pattern of 
zoonotic origin, such as Middle East respiratory syndrome, SARS 
and COVID-19. Ongoing wildlife–human interaction practices 
may continue to pose a significant public health risk in the future 
and was predicted a ‘time bomb’ in a 2007 coronavirus review.w8 
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The COVID-19 pandemic emphasises the need for the rapid 
development and implementation of clear strategies to deal 
with such crises in the care of patients with heart disease. Of 
note during this COVID-19 pandemic crisis, many cardiovas-
cular clinical research studies have been paused or suspended. 
Though it is hoped that the actual acute phase of COVID-19 
infection will be short lived, it is vital that important clinical 
research is continued, given the long- term benefits of ongoing 
clinical research for patients with long- term conditions including 
CVD.w9
COnCLusIOn
The evidence is sparse on the optimal care of older patients 
with ACS with lack of robust RCTs. In this setting, with a 
serious threat imposed by the COVID-19 pandemic in the 
context of rapidly evolving knowledge with much unknown, 
it is important to weigh the risks and benefits of treatment 
strategies offered to patients. In cases where risks outweigh 
the benefits, it might not be an unreasonable option to treat 
such patients with a conservative or a palliative approach. 
Further evidence to elucidate whether invasive management is 
beneficial in older patients with ACS is required. Importantly, 
resumption of ongoing research activities to address these 
gaps is required once of course the acute phase of COVID-19 
pandemic challenges pass.
Additional references can be found in the online supplemen-
tary file.
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